Iptacopan · Fabhalta

Small molecule

Also known as LNP023

Approvedregulatory verdict

Evidence outlook

Approved: Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy, Complement-Mediated Renal Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Chronic Kidney Disease · Phase 3Age-Related Macular Degeneration · Phase 2Generalized Myasthenia Gravis · Phase 3

Also approved (5)
US
  • Complement 3 Glomerulopathy FABHALTA is indicated for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
Product first approved 2023Outside this platform's coverageFDA label
EU
  • Adult patients with complement 3 glomerulopathy (C3G)
  • Monotherapy in adult patients with paroxysmal nocturnal haemoglobinuria (PNH)
Product first approved 2024EMA
JP
  • Paroxysmal nocturnal haemoglobinuria (PNH), adults; Japanese brand name written Fabihalta in katakana; date from the Novartis Japan release of 2024-06-24
Product first approved 2024novartis.com
CN
  • Adult PNH patients who have not previously received complement inhibitor therapy (NMPA notice updated 2024-04-30)
Product first approved 2024NMPA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (15)
Chronic Kidney Disease
Generalized Myasthenia Gravis
IgA Nephropathy
NCT06994845 · Novartis Pharmaceuticals
2025-11-27 – 2030-06-30 · Primary Immunoglobulin A Nephropathy (IgAN)
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT06934967 · Novartis Pharmaceuticals
2025-10-28 – 2031-11-13 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
What this study did
NCT04747613 · Novartis Pharmaceuticals
2021-07-27 – 2027-10-18 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT05630001 · Novartis Pharmaceuticals
2023-04-24 – 2024-10-17 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Other / comorbidity
NCT03955445 · Novartis Pharmaceuticals
2019-10-03 – 2036-05-30 · C3 Glomerulopathy, Immune-complex-membranoproliferative Glomerulonephritis
What this study did
NCT05795140 · Novartis Pharmaceuticals
2024-05-08 – 2032-07-27 · Atypical Hemolytic Uremic Syndrome
What this study did
NCT05935215 · Novartis Pharmaceuticals
2024-02-28 – 2029-07-19 · Atypical Hemolytic Uremic Syndrome
What this study did
NCT05755386 · Novartis Pharmaceuticals
2023-10-02 – 2029-05-31 · IC-MPGN
What this study did
NCT04889430 · Novartis Pharmaceuticals
2022-01-17 – 2026-04-11 · Atypical Hemolytic Uremic Syndrome
What this study did
Phase 2 (11)
Age-Related Macular Degeneration
Chronic Kidney Disease
IgA Nephropathy
NCT06797518 · Novartis Pharmaceuticals
2025-02-21 – 2027-11-27 · Glomerulonephritis, IGA, Immunoglobulin A Nephropathy
What this study did
Paroxysmal Nocturnal Hemoglobinuria
NCT02534909 · Novartis Pharmaceuticals
2015-09-09 – 2022-05-24 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
NCT03439839 · Novartis Pharmaceuticals
2018-04-09 – 2022-02-28 · Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis
What this study did
NCT03896152 · Novartis Pharmaceuticals
2019-04-05 – 2022-02-09 · Paroxysmal Nocturnal Hemoglobinuria
What this study did
Other / comorbidity
NCT06388941 · Novartis Pharmaceuticals
2024-08-05 – 2026-12-30 · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
What this study did
NCT05086744 · Novartis Pharmaceuticals
2021-12-21 – 2024-05-17 · Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
What this study did
NCT04154787 · Novartis Pharmaceuticals
2019-11-23 – 2023-01-20 · Idiopathic Membranous Nephropathy
What this study did
NCT03832114 · Novartis Pharmaceuticals
2019-02-20 – 2021-04-23 · Glomerulonephritis
What this study did
Phase 1 (1)
Early phase / not applicable (2)
Other / comorbidity
NCT07347990 · First Affiliated Hospital of Zhejiang University
2026-08-25 – 2029-12-31 · Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)
What this study did
NCT06847607 · Bing Han
2025-03-01 – 2026-06-30 · AIHA - Warm Autoimmune Hemolytic Anemia, AIHA - Cold Autoimmune Hemolytic Anemia
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Paroxysmal Nocturnal Hemoglobinuria: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Iptacopan (Fabhalta): this drugApprovedSmall moleculeComplement Factor BPartial signal
NCT04558918: At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries.
NCT04820530: Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator.
Eculizumab (Soliris)ApprovedMonoclonal antibodyComplement C5Weak signalFeatured results are safety only in this race
Pegcetacoplan (Empaveli)ApprovedPeptideComplement C3Partial signal
NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666)
Ravulizumab (Ultomiris)ApprovedMonoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
HRS-5965Phase 3UndisclosedComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication
Pozelimab (Veopoz)Phase 3Monoclonal antibodyComplement C5not yet gradedNo reviewed efficacy summary in this indication
FWY003
Phase 2(overall)
UndisclosedComplement Factor B
not yet graded(overall)
No reviewed efficacy summary in this indication
ZaltenibartPhase 2Monoclonal antibodyMASP-3Weak signal
NCT05972967: Interim (data cut-off 8 July 2024): primary endpoints were safety and tolerability; zaltenibart was well tolerated, treatment-related adverse events in 46.2% of patients (mostly mild to moderate), 1 discontinuation for a treatment-emergent serious adverse event. Hemoglobin rose from a mean baseline of 9.26 g/dL by 3.39 g/dL at day 29 and 3.27 g/dL at day 169 on add-on to ravulizumab (N=13), and by 3.85 g/dL at day 309 on monotherapy (N=6, P=0.003).
ALN-CFBPhase 1/2RNA / oligonucleotideComplement Factor Bnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(13 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fabhalta (Iptacopan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated VasculitisActive not recruiting
Est. primary completion 2026-12-30 · NCT06388941 · CT.gov ↗
What to watch
2027 (5)
January 2027 (1)
Phase 3C3GRecruiting
Est. primary completion 2027-01-29 · NCT04817618 · CT.gov ↗
What to watch
April 2027 (1)
Phase 3Generalized Myasthenia GravisActive not recruiting
Est. primary completion 2027-04-30 · NCT06517758 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaActive not recruiting
Est. primary completion 2027-10-18 · NCT04747613 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2IgA NephropathyRecruiting
Est. primary completion 2027-11-27 · NCT06797518 · CT.gov ↗
What to watch
December 2027 (1)
Early phase / not applicableThrombotic Microangiopathy, Hematopoietic Stem Cell Transplantation (HSCT)Recruiting
Est. primary completion 2027-12-31 · NCT07347990 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
Phase 3Atypical Hemolytic Uremic SyndromeRecruiting
Est. primary completion 2028-07-21 · NCT05935215 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3IC-MPGNRecruiting
Est. primary completion 2028-10-27 · NCT05755386 · CT.gov ↗
What to watch
2030 (2)
June 2030 (1)
Phase 3IgA NephropathyRecruiting
Est. primary completion 2030-06-28 · NCT06994845 · CT.gov ↗
What to watch
December 2030 (1)
Phase 3Chronic Kidney DiseaseRecruiting
Est. primary completion 2030-12-04 · NCT04557462 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Phase 3Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2031-10-14 · NCT06934967 · CT.gov ↗
What to watch
2032 (1)
July 2032 (1)
Phase 3Atypical Hemolytic Uremic SyndromeRecruiting
Est. primary completion 2032-07-16 · NCT05795140 · CT.gov ↗
What to watch
2036 (1)
May 2036 (1)
Phase 3C3 Glomerulopathy, Immune-complex-membranoproliferative GlomerulonephritisRecruiting
Est. primary completion 2036-05-30 · NCT03955445 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 July 2026ApprovalFDA grants traditional approval to Fabhalta in primary IgAN
US, FDA · Source ↗
16 October 2025Topline resultAPPLAUSE-IgAN (NCT04578834) Phase 3 final analysis met its primary endpoint
Novartis · Source ↗
20 March 2025ApprovalFDA approves Fabhalta for C3G
US, FDA · Source ↗